One potential explanation for the negative outcome is the lack of genetic stratification of PD patients to enrich for patients with a strong contribution of mitochondrial dysfunction (e.g., biallellic PRKN or PINK1 mutation carriers) as listed in Table 2. This evidence concerns the gene PINK1 and Parkinson disease.